Cited 0 times in
Telbivudine Plus Adefovir Versus Lamivudine Plus Adefovir for Lamivudine-Resistant Chronic Hepatitis B: TeSLA Randomized Trial
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 이정일 | - |
dc.date.accessioned | 2023-11-28T02:55:28Z | - |
dc.date.available | 2023-11-28T02:55:28Z | - |
dc.date.issued | 2021-11 | - |
dc.identifier.issn | 1735-143X | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/196689 | - |
dc.description.abstract | Background: In countries with unavailable tenofovir, a combination of lamivudine (LMV) and adefovir (ADV) is recommended for the treatment of LMV-resistant chronic hepatitis B (CHB). Considering that telbivudine (L-dT) was demonstrated to be superior to LMV in previous studies, L-dT and ADV combination therapy is expected to show better antiviral efficacy than the combination of LMV and ADV in patients with LMV-resistant CHB. Methods: This was a prospective randomized multicenter study. The primary endpoint was Hepatitis B Virus (HBV) DNA reduction after 52 weeks of treatment. The secondary endpoints were HBV DNA undetectability, hepatitis B e antigen seroconversion, the incidence of virological and biochemical breakthroughs, and safety during the study period. Results: A total of 43 LMV-resistant CHB patients were enrolled. Twenty-one were treated with LMV + ADV and 22 with L-dT + ADV. After 52 weeks of antiviral treatment, the HBV DNA reduction showed no significant intergroup difference (-4.54 ± 1.23 log IU/mL in the LMV + ADV group, -4.24 ± 1.46 log IU/mL in the L-dT + ADV group, P = 0.475). There were no significant intergroup differences in HBV DNA undetectability rates, mean HBV DNA level, or hepatitis B e antigen seroconversion rate at 13, 26, 39, and 52 weeks of treatment. In terms of safety, the mean creatine phosphokinase level was significantly higher in the L-dT + ADV group. Conclusions: In the treatment of LMV-resistant CHB, the combination of L-dT and ADV did not show any clinical benefit compared to the combination of LMV and ADV. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | Briefland | - |
dc.relation.isPartOf | HEPATITIS MONTHLY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | Telbivudine Plus Adefovir Versus Lamivudine Plus Adefovir for Lamivudine-Resistant Chronic Hepatitis B: TeSLA Randomized Trial | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Tae Hyung Kim | - |
dc.contributor.googleauthor | Minkoo Kim | - |
dc.contributor.googleauthor | Hyung Joon Yim | - |
dc.contributor.googleauthor | Sang Jun Suh | - |
dc.contributor.googleauthor | Young Kul Jung | - |
dc.contributor.googleauthor | Yeon Seok Seo | - |
dc.contributor.googleauthor | Soon Ho Um | - |
dc.contributor.googleauthor | Jung Il Lee | - |
dc.contributor.googleauthor | Sae Hwan Lee | - |
dc.contributor.googleauthor | Sang Gyun Kim | - |
dc.contributor.googleauthor | In Hee Kim | - |
dc.contributor.googleauthor | Hyoung Su Kim | - |
dc.contributor.googleauthor | Eun Young Cho | - |
dc.contributor.googleauthor | Tae Yeob Kim and Seong Gyu Hwang | - |
dc.identifier.doi | 10.5812/hepatmon.121627 | - |
dc.contributor.localId | A03122 | - |
dc.relation.journalcode | J04298 | - |
dc.identifier.eissn | 1735-3408 | - |
dc.subject.keyword | Adefovir | - |
dc.subject.keyword | Hpatitis B | - |
dc.subject.keyword | Lamivudine Resistance | - |
dc.subject.keyword | Rescue Therapy | - |
dc.subject.keyword | Telbivudine | - |
dc.contributor.alternativeName | Lee, Jung Il | - |
dc.contributor.affiliatedAuthor | 이정일 | - |
dc.citation.volume | 21 | - |
dc.citation.number | 11 | - |
dc.citation.startPage | e121627 | - |
dc.identifier.bibliographicCitation | HEPATITIS MONTHLY, Vol.21(11) : e121627, 2021-11 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.